Sanofi halts global development of its OX40‑ligand antibody amlitelimab for atopic dermatitis, removing a potential competitor to Dupixent and cutting related R&D spend
Executive summary: Sanofi disclosed that it will cease clinical development of amlitelimab for atopic dermatitis and will not seek global regulatory approval for the asset. The move removes a forthcoming biologic competitor from the atopic dermatitis market, reduces Sanofi’s R&D outlay, and signals a reallocation of resources within its immunology portfolio.
Who is involved: Sanofi (sponsor), amlitelimab (OX40‑ligand mAb), patients with moderate‑to‑severe atopic dermatitis, and global health regulators (FDA, EMA, etc.).
Likely next: Sanofi is expected to record any related asset impairment in its forthcoming financial filings and to prioritize other late‑stage immunology candidates or external collaborations.
Sanofi announced that it will not submit amlitelimab, an OX40‑ligand monoclonal antibody, for worldwide regulatory approval in moderate‑to‑severe atopic dermatitis and will discontinue its clinical development. The decision ends a costly Phase III programme and eliminates a potential rival to Dupixent in the crowded biologics market for atopic dermatitis. By stopping the asset, Sanofi avoids further stream, the company can redirect capital and research focus to other immunology projects or external partnerships.
Timeline
- — Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews (GlobeNewswire)
Analysis — what this means
Sectors affected
- Biopharmaceuticals
- Atopic dermatitis therapeutics
- Immunology
Regulatory implications
- Sanofi avoids upcoming Phase III trial expenses and associated regulatory review timelines for amlitelimab in atopic dermatitis.
Sources
- Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews — GlobeNewswire
Related cases
- NovoSense's 66.7% H1 revenue surge highlights strong demand for analog ICs in AI server power
- Antengene posts first-ever profit in 2026 interim results, boosting biotech value creation
- Magnaghi commits €70 million to research and digitalization to advance aerospace control surface technology
- Sunshine Guojian's 2026 interim report highlights continued innovation in China's antibody therapeutics sector
- Lam Research’s $3B+ R&D lab expansion targets faster AI chip innovation to strengthen its competitive edge in semiconductor equipment
- Aureka Biotechnologies secures $100M Series B to develop AI-driven biological world model for accelerated drug discovery